Jaguar Health, Inc. 8K

Jaguar Health reported Q2 2026 financial results reflecting the shift of U.S. Mytesi and Canalevia-CA1 commercialization to Future Pak under a licensing deal and a strategic focus on crofelemer development for rare intestinal failure diseases.

On August 19, 2026, Jaguar Health, Inc. reported its consolidated second quarter 2026 financial results, highlighting the impact of a January 12, 2026 U.S. commercial licensing agreement under which Future Pak’s affiliate Woodward Specialty, LLC became the exclusive U.S. marketer for the Company’s Mytesi and Canalevia-CA1 products, the recognition of initial license revenues and a non-dilutive $2 million holdback payment tied to that agreement, modest ongoing license and federal grant revenues, and a sharp decline in reported prescription product net revenue versus the prior year as U.S. Mytesi and Canalevia-CA1 revenues are now directed to Future Pak, while the Company continues to focus its strategy on developing crofelemer for rare intestinal failure diseases and preparing an NDA package for microvillus inclusion disease by late 2026 with an expected NDA filing in Q2 2027.

Filing Facts

CIK

1585608

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-356915

Alert Tier

6